Abstract
Based on reports of substantial antitumor efficacy of the combination of mitoxantrone (DHAD), 5-fluorouracil (FU) and leucovorin (LV), a clinical trial was performed to attempt augmentation of the dose of DHAD with filgrastim support. The doses and schedules, all intravenous, were DHAD (total dose divided over days 1 and 2), level I, 16 mg/m2; II, 20 mg/m2;III, 24 mg/m2; IV, 32 mg/m2;and LV, 300 mg, followed by FU, 350 mg/m2;,on days 1–3. Filgrastim was given at 5 μg/kg/day subcutaneously on days 4–13. The planned cycle length was 21 days. Three or 4 patients were to be entered at each dose level and the maximum tolerated dose (MTD) was defined as thedose immediately below that which resulted in 2 patients with dose-limiting toxicity (DLT) in cycle 1. Once an apparent MTD was identified, an additional 6 patients were to be entered. Twenty patients (pts) were entered: level I: 3 pts; II: 3 pts; III: 10 pts; IV: 4 pts. The major toxicity was found to be cumulative thrombocytopenia with platelet counts ≤ 20,000/μL occurring after cycle 1 at all levels beyond level I and five pts (25%) were removed from treatment solely because of platelet toxicity. Additional serious toxicities included grade 4 stomatitis in one patient (level IV) and cardiac toxicity in 2 patients with prior doxorubicin exposure. Ten pts had measurable and 8 had evaluable disease, and in 17 pts assessed, 5 (29%)achieved an objective response. The response rates in this study are lower than reported in the literature for the combination of DHAD, 5FU, LV and this may be related to the fact that only 40% of the patients were removed from protocol treatment because of disease progression. On the basis of limited DHAD-dose augmentation, toxicities observed, and modest response rate, the filgrastim-supported DHAD, 5FU, LV regimen as utilized in this study cannot be recommended for further development for treatment of women with metastatic breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Triozzi PL, Rhoades C, Thornton DE: High-dose chemotherapy for breast cancer. Cancer Treat Rev 21: 185–198, 1995
Schiffer LM, Braunschweiger PG, Stragand JJ, Poulakos L: The cell kinetics of human mammary cancers. Cancer 43: 1707–1719, 1979
Saletan S: Mitoxantrone: An active, new antitumor agent with an improved therapeutic index. Cancer Treat Rev 14: 297–303, 1987
Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR: Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells. Cancer Res 40: 671–681, 1980
LeMaistre CF, Herzig R: Mitoxantrone: Potential for use in intensive therapy. Semin Oncol 17(suppl 3): 43–48, 1990
Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571, 1989
Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group Study. J Natl Cancer Inst 83: 1077–1084, 1991
Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K: Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3: 123–132, 1985
Hainsworth JD, Andrews MB, Johnson DH, Greco FA: Mitoxantrone, fluorouracil, and high dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731–1736, 1991
Jones SE, Mennel RG, Brooks B, Westrick MA, Allison MA, Paulson RS, Tilmann K, Rea B: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736–1739, 1991
Wils JA: Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: An effective and well-tolerated regimen for the treatment of advanced breast cancer. Eur J Cancer 29A: 2106–2108, 1993
Swain SM, Honig SF: Mitoxantrone, 5-FU, and leucovorin in breast cancer. Med Ped Oncol 22: 370–374, 1994
Mammoliti S, Merlini L, Caroti C, Gallo L: Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients. Eur J Cancer 30A: 248–249, 1994
Jolivet J, Belanger K, Yelle L, Guevin R, Potvin M, Wilson J, Rudinskas L, Latreille J, Dionne J, Gagne L, Ayoub J: The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. Eur J Cancer 30A: 626–628, 1994
Repetto L, Miglietta L, Gardin G, Lanfranco C, Naso C, Merlini L, Giudici S, Verturino A, Campora E, Testore F, Rosso R: Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat 30: 133–137, 1994
Ingle JN, Kuross SA, Mailliard JA, Loprinzi CL, Jung SH, Nelimark RA, Krook JE, Long HJ: Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy. Cancer 74: 1733–1738, 1994
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Lemmens J, Berteloot P, Thomas J, Wildiers J, Paridaens R: Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. Eur J Cancer 31A: 2114–2115, 1995
Gebbia V, Valenza R, Testa A, Cannata G, Verderame F, Gebbia N: Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer 30A: 1734–1736, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ingle, J.N., Kardinal, C.G., Suman, V.J. et al. Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer. Breast Cancer Res Treat 43, 193–200 (1997). https://doi.org/10.1023/A:1005749115033
Issue Date:
DOI: https://doi.org/10.1023/A:1005749115033